Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observation Study
This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.
Salvatore Del Prete, MD
Sponsor(s)Southwest Oncology Group
ContactEd Hatton, RN at 203-358-8879 or [email protected]
Bennett Cancer Center
Stamford, CT 06902